Clinical Trial

Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls

Study acronym: Shingr'HIV
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of the adjuvanted recombinant Zoster vaccine (RZV, or Shingrix®) in older people (\> 50 years) living with HIV (PLWH) compared to age-matched healthy adults over a 1-year period.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-10-10; most recent amendment 2025-08-28.
Status change: Recruiting → Active, Not Recruiting 2025-04-08
Status change: Not Yet Recruiting → Recruiting 2023-02-21
Trial Details
NCT Number NCT05575830
Lead Sponsor Calmy Alexandra
Conditions RZV Vaccine (Shingrix ®)
Enrollment 225 participants
Start Date 2022-12-14
Primary Completion 2025-04-16 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-05